HSP90AA1 and diabetes mellitus: Integrating these insights with innovative inhibitor design could enable precise targeting of Hsp90 across a range of conditions, including malignancies, neurodegenerative disorders, cardiovascular diseases, and diabetes, thereby maximizing therapeutic efficacy while minimizing adverse effects.